| Overview |
| bs-4269r-100ul |
| CDKN2B Polyclonal Antibody |
| WB, IHC-P, IF(IHC-P) |
| Human, Mouse, Rat, Bovine, Dog, Chicken |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CDKN2B |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 1030 |
| P42772 |
| CDK inhibitory protein; CDK4B Inhibitor; CDKN2B; Cyclin dependent kinase 4 inhibitor B; Cyclin Dependent Kinase Inhibitor 2B; Cyclin dependent kinase inhibitor 2B p15 inhibits CDK4; Cyclin-dependent kinases 4 and 6 binding protein; INK4B; MTS 2; MTS2; Multiple Tumor Supressor 2; p14 CDK inhibitor; p14 INK4b; P15; p15 CDK inhibitor; p15 inhibits CDK4; p15 INK4b; P15INK4B; p15INK4B; TP 15; TP15. |
| p15 INK4b / MTS 2 (Mitotic Inhibitor / Suppressor Protein) is a specific inhibitor of cdk 4 / cdk 6 and is periodically expressed during the cell cycle. Reportedly, p15 INK4b expression is induced approximately 30 fold in human keratinocytes by treatment with TGF beta, suggesting that p15 INK4b may act as an effector of TGF beta mediated cell cycle arrest. p15 INK4b is mapped to chromosome 9p21, a region of frequent loss in a wide variety of cancers. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz